Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGSWW) Other Working Capital Changes (2020 - 2025)

GeneDx Holdings has reported Other Working Capital Changes over the past 6 years, most recently at $5.0 million for Q4 2025.

  • Quarterly results put Other Working Capital Changes at $5.0 million for Q4 2025, up 138.64% from a year ago — trailing twelve months through Dec 2025 was $3.2 million (down 3.77% YoY), and the annual figure for FY2025 was $3.2 million, down 3.77%.
  • Other Working Capital Changes for Q4 2025 was $5.0 million at GeneDx Holdings, up from -$3.2 million in the prior quarter.
  • Over the last five years, Other Working Capital Changes for WGSWW hit a ceiling of $7.5 million in Q3 2022 and a floor of -$6.3 million in Q2 2021.
  • Median Other Working Capital Changes over the past 5 years was $145500.0 (2021), compared with a mean of $581450.0.
  • Biggest five-year swings in Other Working Capital Changes: skyrocketed 43970.59% in 2022 and later plummeted 492.99% in 2025.
  • GeneDx Holdings' Other Working Capital Changes stood at $1.8 million in 2021, then tumbled by 418.6% to -$5.9 million in 2022, then surged by 86.43% to -$797000.0 in 2023, then skyrocketed by 362.36% to $2.1 million in 2024, then skyrocketed by 138.64% to $5.0 million in 2025.
  • The last three reported values for Other Working Capital Changes were $5.0 million (Q4 2025), -$3.2 million (Q3 2025), and $4.5 million (Q2 2025) per Business Quant data.